help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agarwal, A. K.
Right arrow Articles by Garg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agarwal, A. K.
Right arrow Articles by Garg, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*Protein*UniGene
*Substance via MeSH
*Genetics Home Reference
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 1 408
Copyright © 2002 by The Endocrine Society

RAPID COMMUNICATIONS

A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-{gamma} Gene in a Patient with Familial Partial Lipodystrophy

Anil K. Agarwal and Abhimanyu Garg

Department of Internal Medicine, Division of Nutrition and Metabolic Diseases and Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Familial partial lipodystrophies (FPL) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia. Recently, lamin A/C gene mutations were found in patients with FPL, Dunnigan variety. However, the genetic basis of other phenotypes remains unknown. We studied peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}) gene as a candidate gene in seven FPL patients who did not appear to have Dunnigan variety. Analysis of the coding region of PPARG revealed C to T heterozygous mutation at nucleotide 1273 in exon 6 which changes a highly conserved residue, arginine at position 425 to cysteine (R425C) in the patient FX200.21. The patient is a 64-year-old nonHispanic white woman who developed diabetes mellitus and hypertriglyceridemia at age 32 years and lipodystrophy of the extremities and face at age 50 years. She also had hirsutism. Anthropometry and whole body magnetic resonance imaging revealed marked loss of sc fat particularly from the extremities but sc truncal fat was slightly increased. None of the four unaffected family members harbored the mutation. We conclude that heterozygous, R425C, mutation in PPARG could be the molecular basis for one of the familial partial lipodystrophy phenotypes.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
F. F. Chehab
Minireview: Obesity and LipOdystrophy--Where Do the Circles Intersect?
Endocrinology, March 1, 2008; 149(3): 925 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. Z. Duan, M. G. Usher, and R. M. Mortensen
Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature
Circ. Res., February 15, 2008; 102(3): 283 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Kim, L.-W. Huang, K. J. Snow, V. Ablamunits, M. G. Hasham, T. H. Young, A. C. Paulk, J. E. Richardson, J. P. Affourtit, T. Shalom-Barak, et al.
A mouse model of conditional lipodystrophy
PNAS, October 16, 2007; 104(42): 16627 - 16632.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. I. Anghel, E. Bedu, C. D. Vivier, P. Descombes, B. Desvergne, and W. Wahli
Adipose Tissue Integrity as a Prerequisite for Systemic Energy Balance: A CRITICAL ROLE FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma}
J. Biol. Chem., October 12, 2007; 282(41): 29946 - 29957.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A. Ludtke, J. Buettner, H. H-J Schmidt, and H. J Worman
New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand
J. Med. Genet., September 1, 2007; 44(9): e88 - e88.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. A. Hegele, T. R. Joy, S. A. Al-Attar, and B. K. Rutt
Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism
J. Lipid Res., July 1, 2007; 48(7): 1433 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Ludtke, J. Buettner, W. Wu, A. Muchir, A. Schroeter, S. Zinn-Justin, S. Spuler, H. H.-J. Schmidt, and H. J. Worman
Peroxisome Proliferator-Activated Receptor-{gamma} C190S Mutation Causes Partial Lipodystrophy
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2248 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Monajemi, L. Zhang, G. Li, E. H. Jeninga, H. Cao, M. Maas, C. B. Brouwer, E. Kalkhoven, E. Stroes, R. A. Hegele, et al.
Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-{gamma}
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1606 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
E. H. Jeninga, O. van Beekum, A. D. J. van Dijk, N. Hamers, B. I. Hendriks-Stegeman, A. M. J. J. Bonvin, R. Berger, and E. Kalkhoven
Impaired Peroxisome Proliferator-Activated Receptor {gamma} Function through Mutation of a Conserved Salt Bridge (R425C) in Familial Partial Lipodystrophy
Mol. Endocrinol., May 1, 2007; 21(5): 1049 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. Li and T. Leff
Altered Promoter Recycling Rates Contribute to Dominant-Negative Activity of Human Peroxisome Proliferator-Activated Receptor-{gamma} Mutations Associated with Diabetes
Mol. Endocrinol., April 1, 2007; 21(4): 857 - 864.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. L. Boguslavsky, C. L. Stewart, and H. J. Worman
Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy
Hum. Mol. Genet., February 15, 2006; 15(4): 653 - 663.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. A. Hegele
Retinoid X Receptor Heterodimers in the Metabolic Syndrome.
N. Engl. J. Med., November 10, 2005; 353(19): 2088 - 2088.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Garg, O. Cogulu, F. Ozkinay, H. Onay, and A. K. Agarwal
A Novel Homozygous Ala529Val LMNA Mutation in Turkish Patients with Mandibuloacral Dysplasia
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5259 - 5264.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. A. Hegele and R. L. Pollex
Genetic and physiological insights into the metabolic syndrome
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R663 - R669.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Molnar, M. Matilainen, and C. Carlberg
Structural Determinants of the Agonist-independent Association of Human Peroxisome Proliferator-activated Receptors with Coactivators
J. Biol. Chem., July 15, 2005; 280(28): 26543 - 26556.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Capanni, E. Mattioli, M. Columbaro, E. Lucarelli, V. K. Parnaik, G. Novelli, M. Wehnert, V. Cenni, N. M. Maraldi, S. Squarzoni, et al.
Altered pre-lamin A processing is a common mechanism leading to lipodystrophy
Hum. Mol. Genet., June 1, 2005; 14(11): 1489 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. D. Freedman, E.-J. Lee, Y. Park, and J. L. Jameson
A Dominant Negative Peroxisome Proliferator-activated Receptor-{gamma} Knock-in Mouse Exhibits Features of the Metabolic Syndrome
J. Biol. Chem., April 29, 2005; 280(17): 17118 - 17125.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Knouff and J. Auwerx
Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Endocr. Rev., December 1, 2004; 25(6): 899 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Vantyghem, P. Pigny, C. A. Maurage, N. Rouaix-Emery, T. Stojkovic, J. M. Cuisset, A. Millaire, O. Lascols, P. Vermersch, J. L. Wemeau, et al.
Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to a LMNA R482W Mutation Show Muscular and Cardiac Abnormalities
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5337 - 5346.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Al-Shali, H. Cao, N. Knoers, A. R. Hermus, C. J. Tack, and R. A. Hegele
A Single-Base Mutation in the Peroxisome Proliferator-Activated Receptor {gamma}4 Promoter Associated with Altered in Vitro Expression and Partial Lipodystrophy
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5655 - 5660.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Phan, M. Peterfy, and K. Reue
Lipin Expression Preceding Peroxisome Proliferator-activated Receptor-{gamma} Is Critical for Adipogenesis in Vivo and in Vitro
J. Biol. Chem., July 9, 2004; 279(28): 29558 - 29564.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith
The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo
Diabetes Care, July 1, 2004; 27(7): 1660 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Agostini, M. Gurnell, D. B. Savage, E. M. Wood, A. G. Smith, O. Rajanayagam, K. T. Garnes, S. H. Levinson, H. E. Xu, J. W. R. Schwabe, et al.
Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor {gamma}
Endocrinology, April 1, 2004; 145(4): 1527 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Garg
Acquired and Inherited Lipodystrophies
N. Engl. J. Med., March 18, 2004; 350(12): 1220 - 1234.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Koutnikova, T.-A. Cock, M. Watanabe, S. M. Houten, M.-F. Champy, A. Dierich, and J. Auwerx
Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR{gamma} hypomorphic mice
PNAS, November 25, 2003; 100(24): 14457 - 14462.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Gavrilova, M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson, K. R. Dietz, C. J. Nicol, C. Vinson, F. J. Gonzalez, and M. L. Reitman
Liver Peroxisome Proliferator-activated Receptor {gamma} Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass
J. Biol. Chem., September 5, 2003; 278(36): 34268 - 34276.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O'Rahilly
The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor {gamma} and Its Therapeutic Modulation
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2412 - 2421.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Simha, A. K. Agarwal, E. A. Oral, J.-P. Fryns, and A. Garg
Genetic and Phenotypic Heterogeneity in Patients with Mandibuloacral Dysplasia-Associated Lipodystrophy
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2821 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. L. Herbst, L. R. Tannock, S. S. Deeb, J. Q. Purnell, J. D. Brunzell, and A. Chait
Kobberling Type of Familial Partial Lipodystrophy: An underrecognized syndrome
Diabetes Care, June 1, 2003; 26(6): 1819 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. M. Ridker, N. R. Cook, S. Cheng, H. A. Erlich, K. Lindpaintner, J. Plutzky, and R. Y.L. Zee
Alanine for Proline Substitution in the Peroxisome Proliferator-Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction
Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 859 - 863.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. B. Savage, G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al.
Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-{gamma}
Diabetes, April 1, 2003; 52(4): 910 - 917.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. A. Hegele, H. Cao, C. Frankowski, S. T. Mathews, and T. Leff
PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy
Diabetes, December 1, 2002; 51(12): 3586 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Chen, A. Misra, and A. Garg
Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4845 - 4856.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Garg and A. Misra
Hepatic Steatosis, Insulin Resistance, and Adipose Tissue Disorders
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3019 - 3022.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society